Pete Salzmann. Immunovant

Vivek Ra­maswamy en­gi­neers new deal with RTW to take Pe­te Salz­man­n's Im­muno­vant pub­lic

Sev­er­al weeks af­ter pulling out of an IPO for Der­ma­vant, Vivek Ra­maswamy has found a dif­fer­ent route for an­oth­er of his biotechs to go pub­lic.

Im­muno­vant is merg­ing with Health Sci­ences Ac­qui­si­tions Cor­po­ra­tion, a $115 mil­lion blank check com­pa­ny spon­sored by RTW In­vest­ments and backed by Adage Cap­i­tal, Cor­morant, Even­tide and Per­cep­tive Ad­vi­sors. In ad­di­tion to around $100 mil­lion con­firmed to be in the bank, RTW and Roivant, along­side BVF Part­ners, have put to­geth­er a $35 mil­lion pri­vate “bridge fi­nanc­ing.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.